06/06/01

Docket # PF-0059-5 CON

"Express Mail" mailing label number <u>EL 856 156 178 US.</u> I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington D.C. 20231 99 June 6, 2001

By: // Lane 6, 2001

PRE / 1

09/875520 09/875520

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)

Commissioner for Patents Box Patent Application Washington, D.C. 20231

Dear Sir:

This is a request for filing a **CONTINUATION** application under 37 CFR 1.53(b) of pending prior application Serial No.09/364,790, filed on July 30, 1999, which is a divisional application of U.S. application serial number 09/153,751 filed September 15, 1998, now U.S. Patent 5,948,626, which is a divisional application of U.S. application serial number 08/919,706, filed August 29, 1997, now U.S. Patent No. 5,811,520, which is a divisional application of U.S. application serial number 08/652,859, filed May 23, 1996, now U.S. Patent No. 5,663,059, which is a continuation-in-part application of U.S. application serial number 08/644,754, filed May 10, 1996, now abandoned, entitled HUMAN PHOSPHOLIPASE INHIBITOR.

- 1. X Enclosed is a specification corresponding to the prior application, U. S. Application Serial No. 08/644,754 filed May 10, 1996, including the oath or declaration as originally signed. The specification does not contain any subject matter that would have been new matter in the prior application.
- With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the paper copy of the Sequence Listing for the instant continuation application is identical with the computer readable form filed with Serial No. 08/644,754, filed May 10, 1996, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. 08/644,754 as the computer readable form for the instant continuation application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant continuation application.
- 3. X Cancel in this application original claims 3-23, 25-27 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the

interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.

- 4. X The inventor(s) of the invention being claimed in this application is (are): Phillip R. Hawkins, Lynn E. Murray.
- 5. X In accordance with 37 CFR 1.63(d) a copy of the originally signed declaration showing applicant's/applicants' signature(s) as filed on August 9, 1996 is enclosed.
- Amend the specification by inserting after the title: "This application is a continuation application of U.S. application serial number 08/644,754 filed May 10, 1996, all of which applications and patents are hereby incorporated herein by reference."
- 7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity		Basic Fee
				Rate	Fee	\$710.00
Total Claims	20	-20	0	x \$18		\$0
Indep. Claims	1	-3	0	x \$80		\$0
Multiple Deper		\$0				

TOTAL FILING FEE \$710.00

- 8. ___ An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
- 9. X Please charge Deposit Account No. <u>09-0108</u> in the amount of \$<u>710.00</u>.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. <u>09-0108</u>.

A duplicate copy of this Request is enclosed.

- 10. X New formal drawings are enclosed.
- 11. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc, recorded on March 21, 1997, at reel 8418/frame 0805.

- 12. ___ A preliminary amendment is enclosed.
- 13. X Also enclosed Information Disclosure Statement (2 pp., in duplicate); List of References Cited by Applicants (2 pp.); Submission of Formal Drawings (1 p., in duplicate); 22 pages of Formal Drawings 1A-1C, 2A-2N, 3, 4, 5, 6 and 7); and Copy of Revocation of Power of Attorney and Appointment of New Attorneys (2 pp).
- 14. X The power of attorney of the prior application is to:

32		
19		
32		
Reg. No. 33,302 Reg. No. 39,784		
8		
7		
Reg. No. 44,316 Reg. No. 43,168		

X The associate power of attorney in the prior application is to:

Lynn E. Murry	Reg. No. 42,918
Leanne C. Price	Reg. No. 42,090
David G. Streeter	Reg. No. 43.168

- a. ___ An associate power of attorney is attached.
- b. ___ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. \underline{X} Address all future correspondence to:

INCYTE GENOMICS, INC. PATENT DEPARTMENT 3160 Porter Drive

Palo Alto, California 94304 ne: (650) 855-0555 Fay: (650) 845-414

Phone: (650) 855-0555, Fax: (650) 845-4166

Date: By: David S.

David G. Streeter, Ph.D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

- ___ Inventor(s)
- ___ Assignee of complete interest
- X Attorney or agent of record
- __ Filed under 37 CFR 1.34(a)

Registration number if acting under 37 CFR 1.34(a)



cket No.: PF-0059-5 CON

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Patent Application,

Washington, Q.C. By:

Printed:

Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hawkins et al.

Title:

HUMAN PHOSPHOLIPASE INHIBITOR

Serial No.:

To Be Assigned

Filing Date:

Herewith

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Official Draftsman

Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF FORMAL DRAWINGS

Sir:

Transmitted herewith are Figure(s)1A, 1B, 1C, 2A, 2B, 2C, 2D, 2E, 2F, 2G, 2H, 2I, 2J, 2K, 2L, 2M, 2N, 3, 4, 5, 6 and 7 as twenty-two (22) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the reverse side of the drawings.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108. A duplicate copy of this communication is enclosed.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted.

INCYTE GENOMICS, INC

David G. Streeter, Ph.D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

3160 Porter Drive Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 845-4166

79293